Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 7/20 | 0.38 |
| ▸ | BCHE | P06276 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11242681 | 0.80 | CYP3A4 (0.55) | LMNAMAPTCYP3A4NR1I2CYP1A2 | |
| SCHEMBL24591164 | 0.80 | LMNA (0.55) | LMNAMAPTCYP3A4NR1I2CYP1A2 | |
| SCHEMBL11641107 | 0.79 | BCHE (0.51) | LMNAMAPTCYP3A4NR1I2CYP1A2 | |
| SCHEMBL6885550 | 0.78 | KMT2A (0.53) | CYP1A2MAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL5155573 | 0.77 | RAB9A (0.43) | LMNAMAPTCYP3A4NR1I2CYP1A2 | |
| SCHEMBL7781426 | 0.77 | MAPT (0.46) | LMNAMAPTCYP3A4NR1I2CYP1A2 | |
| SCHEMBL9269153 | 0.76 | L3MBTL1 (0.49) | LMNAMAPTCYP3A4NR1I2CYP1A2 | |
| SCHEMBL14051488 | 0.76 | ACHE (0.47) | MAPK1TDP1ACHEALDH1A1 | |
| SCHEMBL9203759 | 0.76 | PRSS1 (0.50) | LMNAMAPTMAPK1MEN1KMT2A | |
| SCHEMBL9493319 | 0.75 | MGLL (0.45) | MAPTALDH1A1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919921-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2024-03-05 | — | — | US | disclosed |
| US-20220289783-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2022-09-15 | — | — | US | disclosed |
| US-11377464-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2022-07-05 | — | — | US | disclosed |
| US-11377464-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2022-07-05 | — | — | US | disclosed |
| EP-3828191-A2 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Galecto Biotech AB (DK) | 2021-06-02 | — | — | EP | disclosed |
| EP-3828191-A2 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Galecto Biotech AB (DK) | 2021-06-02 | — | — | EP | disclosed |
| EP-3250581-B1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2021-01-20 | — | — | EP | disclosed |
| EP-3250581-B1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2021-01-20 | — | — | EP | disclosed |
| US-20200407391-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2020-12-31 | — | — | US | disclosed |
| US-10774102-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2020-09-15 | — | — | US | disclosed |
| US-20170349619-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2017-12-07 | — | — | US | disclosed |
| US-20170349619-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2017-12-07 | — | — | US | disclosed |
| EP-3250581-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | Galecto Biotech AB (DK) | 2017-12-06 | — | — | EP | disclosed |
| WO-2016120403-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016120403-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2016-08-04 | — | — | WO | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20040229858-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | LMNA 2308/4885MAPT 3229/4885CYP3A4 594/4885 |
| US-20200407391-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS2 | LMNA 723/4885MAPT 2518/4885CYP3A4 4312/4885 |
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | LMNA 2312/4885MAPT 3296/4885CYP3A4 609/4885 |
| US-11377464-B2 | Galactoside inhibitor of galectins | LGALS3, LGALS1, LGALS2 | LMNA 743/4885MAPT 2200/4885CYP3A4 4163/4885 |
| US-11919921-B2 | Galactoside inhibitor of galectins | LGALS3, LGALS1, LGALS2 | LMNA 743/4885MAPT 2200/4885CYP3A4 4163/4885 |
| US-20220289783-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS2 | LMNA 723/4885MAPT 2518/4885CYP3A4 4312/4885 |
| US-20170349619-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | LGALS3, LGALS1, LGALS2 | LMNA 349/4885MAPT 2513/4885CYP3A4 4028/4885 |
| US-20040229858-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGB4 | LMNA 2327/4885MAPT 3414/4885CYP3A4 627/4885 |
| US-10774102-B2 | Galactoside inhibitor of galectins | LGALS3, LGALS1, LGALS2 | LMNA 743/4885MAPT 2200/4885CYP3A4 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.